BIOMAT Database Logo BIOMAT Database Logo

Alpha-2b-interferon as single therapy for patients with chronic myeloid leukemia relapsing after T-cell depleted allogeneic bone marrow transplantation. 1990

W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Department of Human Biopathology, University of Rome La Sapienza, Italy.

20 CML patients with hematological (5 pts) or only cytogenetic (15 pts) relapse occurring after allogeneic BMT have been treated with alpha-2b-interferon (IFN) at a starting dose of 5 x 10(6) IU/m2, subcutaneously, three times a week. All 5 patients with hematological relapse achieved hematological remission without reduction of bone marrow Ph1-positive cells. With a median follow-up of 43 months (range 6-48) from the hematological relapse, 3 patients are alive and 2 patients died from non-lymphoid blast crisis. 7 out of 15 patients with only cytogenetic relapse remain in hematological remission at a median of 37 months (range 3-45) from cytogenetic relapse, with 2 patients achieving complete cytogenetic remission confirmed at the molecular level by disappearance of the bcr rearranged band. With a median follow-up of 21 months (range 6-46), 8 patients progressed from cytogenetic to hematological relapse: 4 patients died from blast crisis and the other 4 patients are currently alive in chronic phase. For the 15 patients, the actuarial survival from BMT is 71% at 5 years.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
March 1999, Bone marrow transplantation,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b.
June 1997, Bone marrow transplantation,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Treatment of chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation: the case for giving interferon.
April 1998, Blood,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Juvenile myelomonocytic leukemia relapsing after allogeneic bone marrow transplantation successfully treated with interferon-alpha.
September 2000, Bone marrow transplantation,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
January 1996, The cancer journal from Scientific American,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Deficit of T-cell recovery after allogeneic bone marrow transplantation in chronic myeloid leukemia patients.
January 1995, Anticancer research,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Interleukin-2 after T-cell-depleted allogeneic bone marrow transplantation.
January 1995, Blood,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
T cell-depleted unrelated donor bone marrow transplantation for acute myeloid leukemia.
January 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
April 1996, Bone marrow transplantation,
W Arcese, and F R Mauro, and M Screnci, and G Alimena, and A P Iori, and M R De Cuia, and F Lo Coco, and E Montefusco, and P Fazi, and F Mandelli
Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
January 2000, Archives of medical research,
Copied contents to your clipboard!